Systematic review and meta-analysis comparing the safety and efficacy of remimazolam and propofol in gastrointestinal endoscopy, suggesting a favorable profile for remimazolam.
Remimazolam has demonstrated safety, showing a reduced incidence of hypotension, bradycardia, respiratory depression, and hypoxemia compared to propofol. However, efficacy outcomes including the induction time and total procedure time were comparable between the two groups. However, the results were heterogeneous, which could be due to variability in the perfumed procedures, co-analgesics or dosing.
No takes yet. Share an insight, caveat, or question.
Youseif et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: